Gsk Share Discussion Threads

[romeike] 15/2/2019 11:06

I've had Monty on filter for as long as I can remember but I bet he is still bleating on about GSK being a bond.

[tradermichael] 15/2/2019 10:09

SOLD 2106 @ 1577.20

[zicopele] 14/2/2019 22:31

IC.....don't make me laugh

[ayl30] 14/2/2019 20:40

Tipped in IC tonight I understand

[zicopele] 14/2/2019 19:33

It happens Graham. Ten years ago on a CFD I accidentally bought £1m of gold on margin of 1%.

I could have lost my shirt.

[toffeeman] 14/2/2019 17:50

Who's for a tripple top at 1620 - good short from there?

[grahamite2] 14/2/2019 15:14

Me too. I've been badly underwater most of the time but it came right in the end and meanwhile there have been the dividends.

I actually sold at 17 and bought back at 16, so at first I felt rather smug that come what may I couldn't have done the wrong thing. Then I realized I had bought 3 times as many as I sold so actually I was exposed.

[montyhedge] 14/2/2019 14:10

I like GSK dividend, but not increased for 4 years, thats why GSK ord shares like a bond for me.

[badtime] 14/2/2019 14:09

Wasn't that long ago when you were banging on about GSK's div Monty ..change like the weather :)

[montyhedge] 14/2/2019 12:16

Astra amazing results, their dividend won't be the same, like GSK has been for the last 4 years, 80p.

[wbecki] 14/2/2019 11:55

"Anyone who examines the incidence of failure of drugs in phase three clinical trials knows that even after 10-15 years of development,a drug can come to nought in the latter stages.Patent protection is key to new drug development.If you don’t want new drugs,then fine just allow governments to radically reduce the return on capital by interfering in the current system"

Indeed. Spot on.
Apparently each drug costs up to £1bn to develop and take through to phase 3 trials where even then they often fail on the efficacy front.

Expensive.
Patents there to ensure drug companies recoup their losses on the 8-9/10 that never pass phase 3.

[zicopele] 14/2/2019 11:55

What GSK would give for AZN results which are quite spectacular.

[steeplejack] 14/2/2019 02:10

A dilemma for all governments wishing to control cost of healthcare.Both democrats and republicans are increasingly favouring the increased use of generics as soon as proprietary patents expire but there’s nothing new here.Anyone who examines the incidence of failure of drugs in phase three clinical trials knows that even after 10-15 years of development,a drug can come to nought in the latter stages.Patent protection is key to new drug development.If you don’t want new drugs,then fine just allow governments to radically reduce the return on capital by interfering in the current system.In some instances,the amount charged for certain medication is morally indefensible but such instances are not widespread and are normally “shamed” in the media.Drug companies will be making a very good return on capital for the foreseeable future.

Where drug companies are open to criticism was adroitly identified by Hilary Clinton.Drug companies might spend 25% odd of turnover on R&D but they also spend a considerable amount of money on marketing including “jollies”; for the medical profession,bribery of sorts.This is the sort of exercise which should be penalised.

[essentialinvestor] 13/2/2019 18:06

There's a detailed SA article on their main oncology compound for anyone interested.
It's above my pay grade, just about understand the concept.

[montyhedge] 13/2/2019 16:29

Yes clamp down coming, margins squeezed.

[wbecki] 13/2/2019 16:24

Americans pay 180 percent of what Europeans, Canadians, and Japanese pay for the exact same drugs! Our seniors aren't going to foot the bill for free-riders abroad any longer, HHS Secretary Alex Azar says.

pic.twitter.com/Zj3Bk8lsdE

[montyhedge] 13/2/2019 15:55

Sold GSK 1560p pick up at 1465p after ex div, piled into IAG (British Airways) no stamp duty only three stocks in FTSE 100 no stamp duty.

[abdullla] 13/2/2019 15:52

GSK can now spend the time spent on Advair on shingles.

[alphorn] 13/2/2019 15:49

You always plan for success. ;)

[tradermichael] 13/2/2019 15:45

They must have manufactured stock before the final audit ….. ;o)

[montyhedge] 13/2/2019 15:43

Mylan must have been ready to distribute that generic Advair.
70% discount, GSK can compete surely.

[essentialinvestor] 13/2/2019 14:04

The oncology assets are key to their longer term success.

Short term headwind is potentially a stronger GBP on the back of any BREXIT
resolution. Appreciate that's not a very popular view atm, however think the upside to GBP v USD and in particular EURO, is being underestimated.

[badtime] 13/2/2019 13:31

Happy to hold

[steeplejack] 13/2/2019 08:35

It’s not going to be easy to convince the market that Glaxo’s outlook is markedly improving.Glaxo was the darling of the 1980s and 90s on the back of Zantacs explosive growth supplemented by Ventolin and Fortam.By the turn of the millennium,the best was discounted as the company merged with SKB.The price back then briefly moved up to the low 20 pounds but has been arguably under pressure ever since.When the company is forecasting an earnings decline this year,it takes a bit of faith to look further to earnings progression.Jeffries target price of £17-50 owes as much to the yield support as to any conviction that the company is set to enjoy a burst of growth.To use old parlance,i think Glaxo could be termed a “weak buy”.

Nonetheless,i’m surprised that Glaxo doesn’t react more positively to Jeffries
recommendation.Probably ran it up last week in expectation.There217;s always been a lot of arbitrage play between the ordinary and the ADRs here.The market-makers like nothing better than to hoover up stock here and sell it out in New York and vicerversa for a quick turn.